Tempus AI, Inc. (NASDAQ:TEM) COO Sells $234,803.16 in Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) COO Ryan Fukushima sold 2,868 shares of Tempus AI stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $81.87, for a total transaction of $234,803.16. Following the sale, the chief operating officer now owns 944,460 shares of the company's stock, valued at approximately $77,322,940.20. The trade was a 0.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, February 4th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $62.50, for a total transaction of $1,250,000.00.
• On Tuesday, January 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $39.61, for a total value of $792,200.00.
• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The stock was sold at an average price of $40.23, for a total value of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The stock was sold at an average price of $42.51, for a total value of $5,101,200.00.

Tempus AI Stock Down 11.2 %

NASDAQ TEM traded down $8.57 during mid-day trading on Friday, hitting $68.15. The stock had a trading volume of 14,356,143 shares, compared to its average volume of 14,342,920. The firm's 50 day moving average is $49.75 and its 200 day moving average is $51.44. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $91.45.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently modified their holdings of the business. First Horizon Advisors Inc. acquired a new position in Tempus AI during the third quarter worth about $30,000. Operose Advisors LLC acquired a new position in shares of Tempus AI during the 4th quarter worth approximately $25,000. Farther Finance Advisors LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC increased its stake in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after acquiring an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC purchased a new position in shares of Tempus AI during the 4th quarter worth $49,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TEM. Stifel Nicolaus downgraded shares of Tempus AI from a "buy" rating to a "hold" rating and increased their price target for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Bank of America increased their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a "neutral" rating in a research note on Friday, December 13th. Wolfe Research assumed coverage on Tempus AI in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target for the company. Piper Sandler reiterated a "neutral" rating and set a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Needham & Company LLC restated a "buy" rating and issued a $56.00 price objective on shares of Tempus AI in a research report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.